Review Article
The Pharmacology of Acute Respiratory Distress Syndrome
| Andrea Chamberlain1 and Brian M Varisco2* | |
| 1Division of Pharmacy, Cincinnati Children’s Hospital Medical Center, USA | |
| 2Division of Pediatric Critical Care Medicine, Cincinnati Children’s Hospital Medical Center, USA | |
| Corresponding Author : | Brian M Varisco, MD Assistant Professor Division of Critical Care Medicine Cincinnati Children's Hospital Medical Center 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA Tel: 513-803-2485 Fax: 513-803-3311 E-mail: Brian.Varisco@cchmc.org |
| Received August 26, 2014; Accepted September 18, 2014; Published September 23, 2014 | |
| Citation: Chamberlain A, Varisco BM (2014) The Pharmacology of Acute Respiratory Distress Syndrome. Clin Pharmacol Biopharm 3:120. doi:10.4172/2167-065X.1000120 | |
| Copyright: © 2014 Chamberlain A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
Abstract
Acute Respiratory Distress Syndrome (ARDS) is a common respiratory complication of critical severe illness or injury. Despite steady improvement in outcomes over the last three decades, ARDS remains a common cause of morbidity and mortality in pediatric and adult intensive care units. Due to its extensive burden, ARDS has been the focus of numerous multi-center clinical trials which have attempted to translate animal, ex vivo, and small single center studies into wider practice. Since the results of several of these large studies have been recently published, we sought to review the pharmacology of ARDS, summarize the major non-pharmacologic interventions shown to improve outcome, and update the reader on evolving therapies which may enter clinical practice in the coming decade.
